Introduction: Inflammatory bowel disease (IBD) is an exceptional scenario with regard to
drug targeting, as oral administration has the potential to deliver the drug directly to the site …

The therapeutic management of inflammatory bowel disease (IBD) represents the perfect
scenario for drug targeting to the site (s) of action. While existing formulation-based targeting …

Inflammatory bowel disease (IBD) refers to a gamut of disorders that are characterized by
chronic intestinal inflammation, including ulcerative colitis (UC) and Crohn's disease (CD) …

Inflammatory bowel disease (IBD) is a chronic illness characterized by relapsing
inflammation of the intestines. The disorder is stratified according to the severity and is …

Background Inflammatory bowel disease (IBD) pathophysiology have led to the
development of various compounds that might ameliorate the disease process. Recently …

Inflammatory bowel disease (IBD) includes Crohn's disease and ulcerative colitis and
manifests as a complex and dysregulated immune response. To date, there is no cure for …

Inflammatory bowel disease (IBD) encompasses two idiopathic inflammatory diseases of the
intestinal tract: Crohn's disease and ulcerative colitis. Existing therapy for IBD consists …

The emergence of biologic therapies is arguably the greatest therapeutic advance in the
care of inflammatory bowel disease (IBD) to date, allowing directed treatments targeted at …

Colonic Drug Delivery Systems (CDDS) are especially advantageous for local treatment of
inflammatory bowel diseases (IBD). Site-targeted drug release allows to obtain a high drug …

Current treatment strategies for inflammatory bowel disease (IBD) seek to alleviate the
undesirable symptoms of the disorder. Despite the higher specificity of newer generation …